1. Singh A, Tetreault L, Kalsi-Ryan S, Nouri A, Fehlings MG. Global prevalence and incidence of traumatic spinal cord injury. Clinical Epidemiology. 2014; 6: 309-31.
2. Donovan J, Kirshblum. Clinical trials in traumatic spinal cord injury. Neurotherapeutics. 2018; 15: 654-68.
3. Evaniew N, Dvorak M. Cochrane in CORR: Steroids for acute spinal cord injury (Review). Clin Orthop Relat Res. 2016; 474(1): 19-24.
4. Anwar MK, Shehabi TS, Eid AH. Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci. 2016; 10: 98.
5. Bydon M, Lin J, Macki M, et al. The Current Role of Steroids in Acute Spinal Cord Injury. World Neurosurgery, 2014. Volume 82, Issue 5. Pages 848-854. https://doi.org/10.1016/j.wneu.2013.02.062
6. Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984; 251: 45-52.
7. Bracken MB, Shephard MJ, Collins WF, Holford TR, Baskin DS, Eisenberg HM, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow up data. Results of the second national acute spinal cord injury study. J Neurosurg. 1992; 76(1): 23-31.
8. Bracken MB, Shephard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. National acute spinal cord injury study. JAMA. 1997; 277: 1597-604.
9. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012; 1: CD001406.
10. Liu Z, Yang Y, He L, et al. High-dose methylprednisolone for acute traumatic spinal cord injury : A meta-analysis. Neurology, 2019. 93 (9) e841-e850; DOI: 10.1212/WNL.0000000000007998
11. Sultan I, Lamba N, Liew A, et al. The safety and efficacy of steroid treatment for acute spinal cord injury: A Systematic Review and meta-analysis. Heliyon. 2020;6(2):e03414. doi:10.1016/j.heliyon.2020.e03414